Pallagi E - Search Results

1

Development of a microparticle-based dry powder inhalation formulation of ciprofloxacin hydrochloride applying the quality by design approach.

Karimi K, Pallagi E, Szabó-Révész P, Csóka I, Ambrus R. Karimi K, et al. Among authors: pallagi e. Drug Des Devel Ther. 2016 Oct 12;10:3331-3343. doi: 10.2147/DDDT.S116443. eCollection 2016. Drug Des Devel Ther. 2016. PMID: 27784991 Free PMC article.

2

Adaptation of the quality by design concept in early pharmaceutical development of an intranasal nanosized formulation.

Pallagi E, Ambrus R, Szabó-Révész P, Csóka I. Pallagi E, et al. Int J Pharm. 2015 Aug 1;491(1-2):384-92. doi: 10.1016/j.ijpharm.2015.06.018. Epub 2015 Jun 29. Int J Pharm. 2015. PMID: 26134895

3

New aspects of developing a dry powder inhalation formulation applying the quality-by-design approach.

Pallagi E, Karimi K, Ambrus R, Szabó-Révész P, Csóka I. Pallagi E, et al. Int J Pharm. 2016 Sep 10;511(1):151-160. doi: 10.1016/j.ijpharm.2016.07.003. Epub 2016 Jul 4. Int J Pharm. 2016. PMID: 27386791

4

Preliminary study of nanonized lamotrigine containing products for nasal powder formulation.

Gieszinger P, Csóka I, Pallagi E, Katona G, Jójárt-Laczkovich O, Szabó-Révész P, Ambrus R. Gieszinger P, et al. Among authors: pallagi e. Drug Des Devel Ther. 2017 Aug 23;11:2453-2466. doi: 10.2147/DDDT.S138559. eCollection 2017. Drug Des Devel Ther. 2017. PMID: 28860716 Free PMC article.

5

Extension of quality-by-design concept to the early development phase of pharmaceutical R&D processes.

Csóka I, Pallagi E, Paál TL. Csóka I, et al. Among authors: pallagi e. Drug Discov Today. 2018 Jul;23(7):1340-1343. doi: 10.1016/j.drudis.2018.03.012. Epub 2018 Mar 27. Drug Discov Today. 2018. PMID: 29601866 Free article. Review.

6

Formulation of levodopa containing dry powder for nasal delivery applying the quality-by-design approach.

Bartos C, Pallagi E, Szabó-Révész P, Ambrus R, Katona G, Kiss T, Rahimi M, Csóka I. Bartos C, et al. Among authors: pallagi e. Eur J Pharm Sci. 2018 Oct 15;123:475-483. doi: 10.1016/j.ejps.2018.07.061. Epub 2018 Aug 1. Eur J Pharm Sci. 2018. PMID: 30076956

7

Initial Risk Assessment as part of the Quality by Design in peptide drug containing formulation development.

Pallagi E, Ismail R, Paál TL, Csóka I. Pallagi E, et al. Eur J Pharm Sci. 2018 Sep 15;122:160-169. doi: 10.1016/j.ejps.2018.07.003. Epub 2018 Jul 3. Eur J Pharm Sci. 2018. PMID: 30008428 Free article.

8

Development of spherical iron(II) sulfate heptahydrate-containing solid particles with sustained drug release.

Szabó-Révész P, Farkas B, Gregor T, Nagy K, Pallagi E. Szabó-Révész P, et al. Among authors: pallagi e. Eur J Pharm Biopharm. 2007 May;66(2):193-9. doi: 10.1016/j.ejpb.2006.10.011. Epub 2006 Oct 21. Eur J Pharm Biopharm. 2007. PMID: 17125982

9

Study of thermal behaviour of sugar esters.

Szuts A, Pallagi E, Regdon G Jr, Aigner Z, Szabó-Révész P. Szuts A, et al. Among authors: pallagi e. Int J Pharm. 2007 May 24;336(2):199-207. doi: 10.1016/j.ijpharm.2006.11.053. Epub 2006 Nov 28. Int J Pharm. 2007. PMID: 17187947

10

Application of the QbD-based approach in the early development of liposomes for nasal administration.

Pallagi E, Jójárt-Laczkovich O, Németh Z, Szabó-Révész P, Csóka I. Pallagi E, et al. Int J Pharm. 2019 May 1;562:11-22. doi: 10.1016/j.ijpharm.2019.03.021. Epub 2019 Mar 13. Int J Pharm. 2019. PMID: 30877028

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

25 results

Search Page

Filters